INSU Acquisition Corp. III Announces Pricing of Upsized $218,000,000 Initial Public Offering
INSU Acquisition Corp. III Announces Pricing of Upsized $218,000,000 Initial Public Offering
PHILADELPHIA, PA, Dec. 17, 2020 INSU Acquisition Corp. III (NASDAQ:IIIIU) (the “Company”), a blank-check company sponsored by Cohen & Company (NYSE American: COHN) and formed for the purpose of acquiring or merging with one or more businesses or entities in the insurance industry, today announced the pricing of its upsized initial public offering of 21,800,000 units at a price of $10.00 per unit, for gross proceeds to the Company of $218,000,000. The Company’s units will be listed on the Nasdaq Capital Market under the symbol “IIIIU” and will begin trading on December 18, 2020. Each unit issued in the offering consists of one share of the Company’s Class A common stock and one-third of one warrant, each whole warrant exercisable for one share of Class A common stock at an exercise pric
Progress CEO Yogesh Gupta Elected Co-Chair of MassTLC Board of Trustees
BEDFORD, Mass., Dec. 09, 2020
Progress (NASDAQ: PRGS), the leading provider of products to develop, deploy and manage high-impact business applications, today announced that CEO Yogesh Gupta has been named Co-Chair of the
MassTLC Board of Trustees. Gupta will serve a two-year term initially alongside Vecna Technologies Co-Founder and current MassTLC Co-Chair Debbie Theobald, whose term ends in 2021.
Gupta was elected to the MassTLC Board of Trustees in 2019. In this role, and as a member of the Executive Diversity and Inclusion Steering Committee (EDISC), he was one of the architects of the Council’s 2030 Challenge to double the percentage of Black and Latinx workers in tech over the coming decade, and framer of the recently formed
News Category Global Banking & Finance Reviews
Silverback Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Silverback Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares Silverback Therapeutics, Inc. (Nasdaq: SBTX) (Silverback), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced the closing of its previously announced initial public offering of 13,225,000 shares of its common stock, which includes 1,725,000 shares sold pursuant to the exercise in full by the underwriters of their option to purchase additional shares, at a price to the public of $21.00 per share. Including the option exercise, the aggregate gross
SWI LOSSES ALERT: Bernstein Liebhard is Investigating SolarWinds Corporation For Violations of the Securities Laws
SWI LOSSES ALERT: Bernstein Liebhard is Investigating SolarWinds Corporation For Violations of the Securities Laws
NEW YORK, Dec. 17, 2020 Bernstein Liebhard, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of SolarWinds Corporation (“SolarWinds” or the “Company”) (NYSE: SWI) resulting from allegations that SolarWinds might have issued misleading information to the investing public.
If you
purchased SolarWinds securities, and/or would like to discuss your legal rights and options please visit SWI Shareholder Investigation or contact Matthew E. Guarnero toll free at
Patient Engagement with Physicians on Twitter Doubles During Pandemic
Patient Engagement with Physicians on Twitter Doubles During Pandemic Patient-physician engagement using Twitter has nearly doubled since the start of the pandemic and doctors are increasingly engaging with patients on a wide range of topics, including impact of COVID-19 on regular care, racial inequalities in health care, and the safety and efficacy of vaccines. These key conclusions as well as other pivotal trends are part of a new report by W2O, the leading independent provider of analytics-driven, technology-enabled marketing and communications solutions to the healthcare sector. Even with offices closed, the doctor was always in thanks to Twitter. W2O detected a stunning 93% increase in patient engagement with physician content on the platform since the pandemic began in March 2020. The initial increase was driven almost exclusively by COVID-19-related topics, but evolved to a broader range of health-rel